References

1. ^Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 811–.ISBN 978-3-88763-075-1.
2. ^^abLeysen JE, Niemegeers CJ (1985)."Neuroleptics". In Lajtha A (ed.).Alterations of Metabolites in the Nervous System. Boston, MA.: Springer Science & Business Media. pp. 331–361.ISBN 978-1-4757-6740-7.
3. ^^abMegens AA, Kennis LE (1996). "Risperidone and related 5HT2/D2 antagonists: a new type of antipsychotic agent?".Progress in Medicinal Chemistry.33:185–232.doi:10.1016/s0079-6468(08)70306-0.ISBN 9780444823106.PMID 8776944.
4. ^Hathway DE (31 October 2007).Foreign Compound Metabolism in Mammals. Royal Society of Chemistry. pp. 302–.ISBN 978-1-84755-608-0.
5. ^Liegeois JF, Bruhwyler J, Rogister F, Delarge J (April 1995)."Diarylazepine derivatives as potent atypical neuroleptic drugs: recent advances".Current Medicinal Chemistry.1 (6). Bentham Science Publishers:471–501.doi:10.2174/092986730106220216114910.S2CID 87829622.
6. ^^abcdeBarnes TR (22 October 2013).Antipsychotic Drugs and Their Side-Effects. Elsevier Science. pp. 28, 34.ISBN 978-1-4832-8810-9.
7. ^American College of Neuropsychopharmacology (1978).Psychopharmacology: a generation of progress. Raven Press. p. 514.ISBN 978-0-89004-191-8.
8. ^Thompson KJ, Khajehali E, Bradley SJ, Navarrete JS, Huang XP, Slocum S, et al. (September 2018)."DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDsin Vitro andin Vivo".ACS Pharmacology & Translational Science.1 (1):61–72.doi:10.1021/acsptsci.8b00012.PMC 6407913.PMID 30868140.
9. ^Chen X, Choo H, Huang XP, Yang X, Stone O,Roth BL, Jin J (March 2015)."The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs".ACS Chemical Neuroscience.6 (3):476–484.doi:10.1021/cn500325v.PMC 4368042.PMID 25587888.